EU and US could reach trade deal this weekend - Reuters
On Monday, Acadia Pharmaceuticals shares saw an uptick in their price target from Morgan Stanley (NYSE:MS), rising to $24 from the previous $20, while the firm kept an Equalweight rating on the stock. The revision comes in the wake of a favorable legal ruling for the company’s key product, Nuplazid. The stock has already shown strong momentum, posting a remarkable 27% gain in the past week, according to InvestingPro data.
The U.S. District Court for the District of Delaware recently delivered a decision that sided with Acadia concerning the ’721 formulation patent of Nuplazid, a treatment for Parkinson’s disease psychosis. This court ruling extends the patent protection for Nuplazid until 2038, an eight-year extension beyond the previously anticipated 2030 expiration. The company, currently valued at $3.73 billion, has demonstrated strong financial health with an EXCELLENT rating from InvestingPro’s comprehensive analysis.
Morgan Stanley’s analyst noted the significance of this legal victory for Acadia, stating that the removal of the anticipated decline in revenues post-2030 has led to the increase in the price target. The new patent expiration date allows Acadia to maintain exclusivity over Nuplazid, which is a critical aspect of the company’s revenue stream. The company has already demonstrated strong revenue growth of 22.4% over the last twelve months, with a healthy gross profit margin of nearly 60%.
Nuplazid is currently the only medication approved by the FDA specifically for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. With this extended patent protection, Acadia is poised to continue capitalizing on its unique market position.
The stock’s new price target reflects Morgan Stanley’s updated valuation model for Acadia, which now accounts for the extended period of market exclusivity for Nuplazid. This development is a significant boon for the company, ensuring its competitive edge in the pharmaceutical market for a longer duration.
In other recent news, Acadia Pharmaceuticals has achieved a significant legal victory in its patent litigation concerning the drug Nuplazid. The U.S. District Court for the District of Delaware ruled in favor of Acadia, confirming the validity of its ’721 patent and extending exclusivity for the 34 mg capsule formulation of Nuplazid until 2038. This decision prevents Aurobindo Pharma (NSE:ARBN) from introducing a generic version, ensuring Acadia’s market exclusivity. Following this ruling, several analyst firms have adjusted their price targets for Acadia. H.C. Wainwright increased its target to $32, maintaining a Buy rating, while Oppenheimer raised its target to $19 with a Perform rating. BMO Capital Markets reaffirmed an Outperform rating and held its price target at $24. These adjustments reflect confidence in Acadia’s strengthened intellectual property position and its potential impact on future revenue. The court’s decision is a pivotal moment for Acadia, securing its competitive edge in the pharmaceutical industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.